Kidney Week 2025 Early Program - Glomerular Diseases: 2025 Update-Potential of Antibody Discovery to Change Podocytopathy Classification and Management

Video Transcription

Video Summary

Dr. Kristen Meliombro reviews how autoantibody discovery—especially antibodies to the slit-diaphragm protein nephrin—could reshape how “podocytopathies” (minimal change disease and FSGS without immune-complex deposits) are classified and managed. Because these disorders likely represent a spectrum of immune-mediated podocyte injury, histology alone may be insufficient. Multiple cohorts show anti-nephrin antibodies in sizable subsets: roughly 29–69% of adults with active/untreated minimal change disease, ~9–40% of primary FSGS, and up to 80–90% of nephrotic, untreated children. Antibody levels generally track with disease activity (proteinuria), may predict shorter relapse-free intervals, and pre-transplant positivity is associated with recurrent post-transplant diffuse podocytopathy/FSGS risk. Pediatric data suggest anti-nephrin positivity is enriched in steroid-sensitive disease and uncommon in multidrug-resistant cases, hinting at predictive value for treatment response.<br /><br />Mechanistic studies support pathogenicity: immunizing animals with nephrin or transferring patient IgG can rapidly induce proteinuria, foot process effacement, slit-diaphragm IgG, and nephrin phosphorylation/endocytosis-related signaling changes.<br /><br />Key challenges include assay standardization (ELISA variants vs immunoprecipitation/Western) and expanding beyond nephrin: “anti-slit” antibodies and other targets (podocin, CARL1, annexin A2, etc.) may define additional biologic subtypes with prognostic and therapeutic implications.

Asset Subtitle

Kristin Meliambro

Meta Tag

Module GLOM

Speaker Kristin Meliambro

Keywords

anti-nephrin antibodies

minimal change disease

primary FSGS

podocytopathies classification

immune-mediated podocyte injury

post-transplant recurrence risk

assay standardization (ELISA vs immunoprecipitation/Western)